Melanoma Research最新文献_第10页

Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response. 达非尼-曲美替尼诱导的白癜风样色素沉着减少：临床反应的潜在标志物。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-10-25 DOI: 10.1097/CMR.0000000000000918

Elena Carmona-Rocha, Ivana Sullivan, Oriol Yélamos

引用次数: 0

Mucosal melanoma: from molecular landscape to current treatment strategies. 粘膜黑色素瘤：从分子景观到当前的治疗策略。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1097/CMR.0000000000000916

Jane Mattei, Eduardo N Trindade, Marcio F Chedid

引用次数: 0

First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma. 首次去办公室进行可疑皮肤病变评估，以此作为高危黑色素瘤的预测指标。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-10-25 DOI: 10.1097/CMR.0000000000000930

Rose Parisi, Hemali Shah, Emily Everdell, Paul Feustel, Lindy Davis

引用次数: 0

Recent advances of artificial intelligence in melanoma clinical practice. 人工智能在黑色素瘤临床实践中的最新进展。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-09-04 DOI: 10.1097/CMR.0000000000000922

Zijun Lin, Haoyan Shen, Xinguang Liu, Wanrui Ma, Mingfa Wang, Jie Ruan, Hongbin Yu, Sha Ma, Xuerong Sun

引用次数: 0

Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study. 端粒长度与皮肤黑色素瘤风险增加相关：一项孟德尔随机化研究。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1097/CMR.0000000000000917

Mingjuan Liu, Yining Lan, Hanlin Zhang, Xinyi Zhang, Mengyin Wu, Leyan Yang, Jia Zhou, Meiyi Tong, Ling Leng, Heyi Zheng, Jun Li, Xia Mi

引用次数: 0

Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition. 直接的早期生长反应-1敲低可降低黑色素瘤的生存能力，而不依赖于丝裂原激活的细胞外信号相关激酶抑制。

IF 1.5 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1097/CMR.0000000000000921

David R Miley, Cynthia M Andrews-Pfannkoch, Jose S Pulido, Samantha A Erickson, Richard G Vile, Michael P Fautsch, Alan D Marmorstein, Lauren A Dalvin

{"title":"Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.","authors":"David R Miley, Cynthia M Andrews-Pfannkoch, Jose S Pulido, Samantha A Erickson, Richard G Vile, Michael P Fautsch, Alan D Marmorstein, Lauren A Dalvin","doi":"10.1097/CMR.0000000000000921","DOIUrl":"10.1097/CMR.0000000000000921","url":null,"abstract":"To investigate downstream molecular changes caused by mitogen-activated protein kinase (MEK) inhibitor treatment and further explore the impact of direct knockdown of early growth response-1 ( EGR1 ) in melanoma cell culture. RNA-sequencing (RNA-Seq) was performed to determine gene expression changes with MEK inhibitor treatment. Treatment with MEK inhibitor (trametinib) was then assessed in two cutaneous (MEL888, MEL624) and one conjunctival (YUARGE 13-3064) melanoma cell line. Direct knockdown of EGR1 was accomplished using lentiviral vectors containing shRNA. Cell viability was measured using PrestoBlueHS Cell Viability Reagent. Total RNA and protein were assessed by qPCR and SimpleWestern. RNA-Seq demonstrated a profound reduction in EGR1 with MEK inhibitor treatment, prompting further study of melanoma cell lines. Following trametinib treatment of melanoma cells, viability was reduced in both cutaneous (MEL888 26%, P < 0.01; MEL624 27%, P < 0.001) and conjunctival (YUARGE 13-3064 33%, P < 0.01) melanoma compared with DMSO control, with confirmed EGR1 knockdown to 0.04-, 0.01-, and 0.16-fold DMSO-treated levels (all P < 0.05) in MEL888, MEL624, and YUARGE 13-3064, respectively. Targeted EGR1 knockdown using shRNA reduced viability in both cutaneous (MEL624 78%, P = 0.05) and conjunctival melanoma (YUARGE-13-3064 67%, P = 0.02). RNA-Sequencing in MEK inhibitor-treated cells identified EGR1 as a candidate effector molecule of interest. In a malignant melanoma cell population, MEK inhibition reduced viability in both cutaneous and conjunctival melanoma with a profound downstream reduction in EGR1 expression. Targeted knockdown of EGR1 reduced both cutaneous and conjunctival melanoma cell viability independent of MEK inhibition, suggesting a key role for EGR1 in melanoma pathobiology.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"482-491"},"PeriodicalIF":1.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10178012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanocytic neoplasms in neurofibromatosis type 1: a systematic review. 1型神经纤维瘤病中的黑色素细胞肿瘤：一项系统综述。

IF 1.5 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-08-14 DOI: 10.1097/CMR.0000000000000912

Summer N Meyer, Elanee Simmons, Amy C Studer, Katherine A Rauen, Maija Kiuru

{"title":"Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.","authors":"Summer N Meyer, Elanee Simmons, Amy C Studer, Katherine A Rauen, Maija Kiuru","doi":"10.1097/CMR.0000000000000912","DOIUrl":"10.1097/CMR.0000000000000912","url":null,"abstract":"Neurofibromatosis type 1 ( NF1 ) is commonly mutated in melanoma, yet the risk of melanoma in individuals with NF1 is incompletely understood. We performed a systematic review to investigate the risk and characteristics of melanoma and melanocytic nevi in NF1 individuals. PubMed was searched for articles describing NF1 individuals with melanoma, or melanocytic nevi. Those with cutaneous and ocular melanomas were compared to the general population using Surveillance, Epidemiology, and End Results data. Fifty-three articles describing 188 NF1 patients were included (melanoma n = 82, melanocytic nevi n = 93, melanocytic nevi, and melanoma n = 13). Compared to the general population, NF1 patients with cutaneous melanomas had earlier melanoma diagnoses (49.1 vs. 58.6 years, P = 0.012), thicker tumors (3.7 vs. 1.2 mm, P = 0.006), and more frequent disease-specific deaths (27.3% vs. 8.6%, P = 0.005) with shorter survival (12.9 vs. 34.2 months, P = 0.011). Ocular melanomas made up 15.0% of all melanomas in NF1 patients versus 1.5% in the general population ( P < 0.001). In pooling all population-based studies describing melanoma in NF1 populations, NF1 individuals had 2.55 higher odds of having melanoma compared to the general population. A nevus spilus was commonly reported among NF1 individuals with nevi (44.8%, 39/87). Our findings suggest that NF1 individuals may have a higher risk for developing melanomas and tend to have thicker melanomas and worse survival compared to the general population, highlighting the importance of cutaneous and ophthalmologic surveillance in NF1 patients. Our review also supports the association between NF1 and nevus spilus.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"437-446"},"PeriodicalIF":1.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9993801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis. 微小RNA-141-3p通过成纤维细胞生长因子13介导的丝裂原活化蛋白激酶轴在人类皮肤黑色素瘤生长和转移中的抑制作用。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-03-21 DOI: 10.1097/CMR.0000000000000873

Haojan Yang, Jiateng Zhou, Dongdong Li, Shengbo Zhou, Xinyi Dai, Xinchao Du, Hailei Mao, Bin Wang

{"title":"The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis.","authors":"Haojan Yang, Jiateng Zhou, Dongdong Li, Shengbo Zhou, Xinyi Dai, Xinchao Du, Hailei Mao, Bin Wang","doi":"10.1097/CMR.0000000000000873","DOIUrl":"10.1097/CMR.0000000000000873","url":null,"abstract":"Human cutaneous melanoma (CM) is a highly invasive malignancy arising from melanocytes, and accompanied by ever-increasing incidence and mortality rates worldwide. Interestingly, microRNAs (miRNAs) possess the ability to regulate CM cell biological functions, resulting in the aggressive progression of CM. Nevertheless, a comprehensive understanding of the underlying mechanism remains elusive. Accordingly, the current study sought to elicit the functional role of miR-141-3p in human CM cells in association with fibroblast growth factor 13 (FGF13) and the MAPK pathway. First, miR-141-3p expression patterns were detected in human CM tissues and cell lines, in addition to the validation of the targeting relationship between miR-141-3p and FGF13. Subsequently, loss- and gain-of-function studies of miR-141-3p were performed to elucidate the functional role of miR-141-3p in the malignant features of CM cells. Intriguingly, our findings revealed that FGF13 was highly expressed, whereas miR-141-3p was poorly expressed in the CM tissues and cells. Further analysis highlighted FGF13 as a target gene of miR-141-3p. Meanwhile, overexpression of miR-141-3p inhibited the proliferative, invasive, and migratory abilities of CM cells, while enhancing their apoptosis accompanied by downregulation of FGF13 and the MAPK pathway-related genes. Collectively, our findings highlighted the inhibitory effects of miR-141-3p on CM cell malignant properties via disruption of the FGF13-dependent MAPK pathway, suggesting a potential target for treating human CM.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"492-505"},"PeriodicalIF":2.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9205121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma. pSTAT5与增厚或溃疡原发性皮肤黑色素瘤患者生存率的提高有关

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-08-10 DOI: 10.1097/CMR.0000000000000915

Samuel X Tan, Sharene Chong, Casey Rowe, Magdalena Claeson, James Dight, Chenhao Zhou, Mathieu P Rodero, Maryrose Malt, B Mark Smithers, Adele C Green, Kiarash Khosrotehrani

{"title":"pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.","authors":"Samuel X Tan, Sharene Chong, Casey Rowe, Magdalena Claeson, James Dight, Chenhao Zhou, Mathieu P Rodero, Maryrose Malt, B Mark Smithers, Adele C Green, Kiarash Khosrotehrani","doi":"10.1097/CMR.0000000000000915","DOIUrl":"10.1097/CMR.0000000000000915","url":null,"abstract":"Identifying prognostic biomarkers to predict clinical outcomes in stage I and II cutaneous melanomas could guide the clinical application of adjuvant and neoadjuvant therapies. We aimed to investigate the prognostic value of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) as a biomarker in early-stage melanoma. This study evaluated all initially staged Ib and II melanoma patients undergoing sentinel node biopsy at a tertiary centre in Brisbane, Australia between 1994 and 2007, with survival data collected from the Queensland Cancer Registry. Primary melanoma tissue from 189 patients was analysed for pSTAT5 level through immunohistochemistry. Cox regression modelling, with adjustment for sex, age, ulceration, anatomical location, and Breslow depth, was applied to determine the association between pSTAT5 detection and melanoma-specific survival. Median duration of follow-up was 7.4 years. High pSTAT5 detection was associated with ulceration and increased tumour thickness. However, multivariate analysis indicated that high pSTAT5 detection was associated with improved melanoma-specific survival (hazard ratio: 0.15, 95% confidence interval: 0.03-0.67) as compared to low pSTAT5 detection. This association persisted when pSTAT5 detection was limited to immune infiltrate or the vasculature, as well as when sentinel node positivity was accounted for. In this cohort, staining for high-pSTAT5 tumours identified a subset of melanoma patients with increased survival outcomes as compared to low-pSTAT5 tumours, despite the former having higher-risk clinicopathological characteristics at diagnosis. pSTAT5 is likely an indicator of local immune activation, and its detection could represent a useful tool to stratify the risk of melanoma progression.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"1 1","pages":"506-513"},"PeriodicalIF":2.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46983586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing. 孤儿药物tebentafusp治疗转移性葡萄膜黑色素瘤患者的成本效益分析和基于价值的定价呼吁。

IF 2.2 4区医学

Melanoma Research Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1097/CMR.0000000000000919

Shaohong Luo, Chen Xie, Ningning Lin, Dong Lin, Dian Gu, Shen Lin, Xiaoting Huang, Xiongwei Xu, Xiuhua Weng

{"title":"Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.","authors":"Shaohong Luo, Chen Xie, Ningning Lin, Dong Lin, Dian Gu, Shen Lin, Xiaoting Huang, Xiongwei Xu, Xiuhua Weng","doi":"10.1097/CMR.0000000000000919","DOIUrl":"10.1097/CMR.0000000000000919","url":null,"abstract":"The normative regimens recommendations for treating metastatic uveal melanoma (mUM) are absent in the US. Recently, a phase III randomized clinical trial revealed that tebentafusp yielded a conspicuously longer overall survival than the control group. Based on the prominent efficacy, this study aimed to assess whether tebentafusp is cost-effective compared to the control group in patients with untreated mUM. A three-state partitioned survival model was developed to assess the costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) from the perspective of US payers. Scenario analyses and sensitivity analyses were conducted to explore the conclusion uncertainty. Compared with control group, tebentafusp therapy yielded an additional 0.47 QALYs (1.19 vs. 0.72 QALYs) and an incremental cost of $444 280 ($633 822 vs. $189 542). The resultant ICER of $953 230/QALY far outweighed the willingness-to-pay threshold of $200 000/QALY. The ICER was always more than $750 000/QALY in all the univariable and probabilistic sensitivity analyses. Scenario analyses indicated that reducing the unit price of tebentafusp to $33.768/µg was associated with a favorable result of tebentafusp being cost-effective. For treatment-naive patients with mUM, the cost of tebentafusp therapy was not worth the improvement in survival benefits at the current price compared to the investigator's choice of therapy. The cost-effectiveness of tebentafusp could be promoted using value-based pricing.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"525-531"},"PeriodicalIF":2.2,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10178011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0